Pizosept 1.125

Indications

PIZOSEPT 1.125 is used for the treatment of moderate to severe infections caused by susceptible bacteria, including:

• Respiratory Tract Infections: Including pneumonia, bronchitis, and other lower respiratory infections.
• Urinary Tract Infections (UTIs): Complicated urinary tract infections caused by resistant bacteria.
• Intra-abdominal Infections: Including infections such as peritonitis, abscesses, and cholangitis.
• Skin and Soft Tissue Infections: Caused by susceptible bacteria.
• Gynecological Infections: Including pelvic inflammatory disease (PID).
• Bacteremia: Bloodstream infections caused by susceptible organisms.
• Sepsis: Severe systemic infections or sepsis caused by resistant organisms.

Piperacillin provides activity against a wide range of Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa, while Tazobactam helps to extend the spectrum by inhibiting beta-lactamase enzymes produced by bacteria.

Dosage and Administration

• Route of Administration: Intravenous (IV) injection or infusion.
• Typical Dose for Adults:
  • Mild to Moderate Infections: Typically, 1.125 gm every 6-8 hours. The dose may be increased in more severe infections.
  • Severe Infections: The dose may be increased to 2.25 gm every 6 hours.
  • Duration of Therapy: Usually administered for 7 to 14 days depending on the severity of the infection.
  • IV Administration: Administer over a period of 30 minutes for each dose.
• Renal Impairment: Dose adjustments may be needed for patients with renal impairment. For patients with creatinine clearance < 40 mL/min, the dosing interval may need to be extended.

Precautions

• Hypersensitivity: Contraindicated in patients with a known allergy to penicillins, cephalosporins, or any component of the product.
• Beta-lactam Allergy: Caution is needed in patients with a history of severe allergic reactions to other beta-lactam antibiotics (e.g., penicillin or cephalosporins).
• Renal Impairment: Dose adjustments may be necessary in patients with impaired renal function.
• Hematologic Issues: Long-term use of this medication may lead to hematologic reactions, such as thrombocytopenia or leukopenia.
• Clostridium difficile-associated Diarrhea (CDAD): Prolonged use of antibiotics, including Piperacillin/Tazobactam, may result in an overgrowth of Clostridium difficile, leading to severe diarrhea. Monitor for symptoms.
• Pregnancy and Breastfeeding: Category B (U.S. FDA classification) for pregnancy, meaning it should be used during pregnancy only if clearly needed. It is excreted in breast milk, so caution is advised while breastfeeding.

Benefits

• Broad-Spectrum Activity: Effective against a wide range of both Gram-positive and Gram-negative bacteria, including many beta-lactamase-producing organisms, due to the combination of Piperacillin and Tazobactam.
• Enhanced Efficacy: Tazobactam enhances the activity of Piperacillin by inhibiting bacterial beta-lactamases, making it effective against otherwise resistant organisms.
• Treatment of Severe Infections: Ideal for severe and complicated infections, including pneumonia, sepsis, and intra-abdominal infections, often caused by multi-drug resistant bacteria.
• IV Formulation for Rapid Action: The IV formulation allows for quick therapeutic levels in critically ill patients, leading to faster relief from severe infections.
• Well-Tolerated: Generally well-tolerated with a low incidence of adverse reactions when administered appropriately.